Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that its Chief Executive Officer,

SELLAS™ Life Sciences Group (SELLAS™), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancer, today announced that results from a...

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the...

Beyond Celiac announced today that Alice Bast, Chief Executive Officer, was selected to share her experience in creating innovative patient engagement strategies at the International Society for...

Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to...